FierceBiotech

I-Mab lays off 27% of workforce after pivoting to CLDN18.2 bispecific

I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...
FierceBiotech

AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space

AbbVie has put I-Mab out of its misery. More than a year after scrapping a pair of clinical trials, the Big Pharma has cut its ties to the anti-CD47 antibody lemzoparlimab altogether and deprived ...
Benzinga.com

I-MAB Analyst Ratings

The latest price target for I-MAB (NASDAQ:IMAB) was reported by Leerink Partners on October 3, 2025. The analyst firm set a price target for $9.00 expecting IMAB to rise to within 12 months (a ...
Hosted on MSN

Everest Medicines announces strategic equity investment in I-Mab

Everest Medicines announced that it has made a strategic equity investment in I-Mab (IMAB). Rogers Yongqing Luo, CEO of Everest Medicines, said, “As a biotech pioneer in China, Everest has built ...
Nasdaq

I-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric Cancer Patients

I-Mab announced positive results from a Phase 1b study of its bispecific antibody, givastomig, which targets Claudin 18.2 and 4-1BB for treating Claudin 18.2-positive gastric cancers. The study, ...
Nasdaq

I-Mab Completes Enrollment Ahead of Schedule in First Dose Expansion Cohort of Givastomig Study, Doses First Patient in Second Cohort

I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer. The study ...